Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-30

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radiation therapy is the main treatment for nasopharyngeal carcinoma (NPC), and standard care for advanced NPC often includes combination chemotherapy and radiation (CCRT). However, many patients experience serious side effects, such as painful mouth sores (Radiation-Induced Oral Mucositis, RTOM). These side effects can be so severe that they lower a patient's ability to adhere to treatment, potentially making the CCRT less effective. Studies have shown that a significant number of patients stop treatment early due to this toxicity.

Current clinical guidelines from organizations like MASCC/ISOO and ESMO agree that preventing RTOM is crucial, but there is currently no specific drug that works for everyone.

This study aims to investigate a new approach: using Sapylin, a biological immune regulator, delivered through an atomized inhaler. Preliminary research suggests Sapylin delivered this way may enhance the effectiveness of chemotherapy and boost the body's immunity.

The main purpose of this study is to determine the effect of Sapylin inhalation on the incidence and severity of RTOM, and to evaluate its safety and impact on the overall success of CCRT.

By participating, you will help researchers find a high-efficiency, low-toxicity method to improve CCRT outcomes and manage RTOM for future NPC patients and specialists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.

NCT06854510

Nasopharyngeal Cancinoma (NPC)

RECRUITING PHASE2/PHASE3

Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma

NCT07189572

Otitis Media Otitis Media With Effusion After Nasopharyngeal Carcinoma Radiotherapy Side Effects +2 more

NOT_YET_RECRUITING PHASE3

A Study of High-Risk Oral Cavity Cancer

NCT00934739

Oral Cavity Cancer

TERMINATED PHASE2/PHASE3

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

NCT07311772

Nasopharyngeal Cancinoma (NPC) Radiation-induced Oral Mucositis

RECRUITING PHASE3

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538

Oral Mucositis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma (NPC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sapylin Group

CCRT combined with Sapylin atomized inhalation (1 KE/time, QD from day 1 till the end of radiotherapy).

Group Type EXPERIMENTAL

CCRT with Cisplatin

Intervention Type COMBINATION_PRODUCT

Patients receive cisplatin-based CCRT: cisplatin 80-100mg/m2, Q3W, three times during CCRT. Radiation dose: PTVnx: 69.96Gy/33F, PTV1: 60.06Gy/33F, PTV2: 54.12Gy/33F.

Sapylin

Intervention Type DRUG

Atomized inhalation, 1 KE/time, QD from day 1 of CCRT until the end of radiotherapy.

Dexamethasone Group

CCRT combined with Dexamethasone atomized inhalation (10 mg/time, QD from day 1 till the end of radiotherapy).

Group Type ACTIVE_COMPARATOR

CCRT with Cisplatin

Intervention Type COMBINATION_PRODUCT

Patients receive cisplatin-based CCRT: cisplatin 80-100mg/m2, Q3W, three times during CCRT. Radiation dose: PTVnx: 69.96Gy/33F, PTV1: 60.06Gy/33F, PTV2: 54.12Gy/33F.

Dexamethasone

Intervention Type DRUG

Dexamethasone (10 mg per administration) via atomized inhalation once daily (QD).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CCRT with Cisplatin

Patients receive cisplatin-based CCRT: cisplatin 80-100mg/m2, Q3W, three times during CCRT. Radiation dose: PTVnx: 69.96Gy/33F, PTV1: 60.06Gy/33F, PTV2: 54.12Gy/33F.

Intervention Type COMBINATION_PRODUCT

Sapylin

Atomized inhalation, 1 KE/time, QD from day 1 of CCRT until the end of radiotherapy.

Intervention Type DRUG

Dexamethasone

Dexamethasone (10 mg per administration) via atomized inhalation once daily (QD).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage III-IVa NPC (AJCC 8th edition) diagnosed via pathology in a tertiary hospital;
* No previous radiotherapy, chemotherapy, surgery, immunization, or targeted therapy;
* Karnofsky Performance Status score ≥80;
* Intact and normal oral mucosa before treatment;
* Age 18-75 years;
* Voluntary participation and provision of informed consent in person;
* Routine blood examination: white blood cell count ≥4.0×109/L, hemoglobin ≥100g/L, neutrophil count ≥1.5×10\^9/L, and platelet count ≥100×10\^9/L;
* Biochemical examination: total bilirubin ≤1.5×the upper limit of the normal range (ULN), alanine aminotransferase and aspartate aminotransferase ≤2×ULN, and estimated glomerular filtration rate ≥60 mL/min.

Exclusion Criteria

* With other malignant tumors in the past or present and/or distant metastasis during treatment;
* Who have undergone surgery, chemoradiotherapy, and targeted immunotherapy;
* With a history of asthma, rash, urticaria, and other allergic diseases;
* With a history of autoimmune diseases, connective tissue diseases, and diabetes mellitus that significantly affect the healing of the oral mucosa;
* With concomitant diseases, such as heart disease, kidney disease, and acute infectious diseases, which are judged by the investigator to seriously endanger the safety of patients or affect the completion of the study;
* Who are breastfeeding, pregnant, or planning to become pregnant during the study;
* With known allergies to the therapeutic agents and penicillin used in the trial;
* Mental or nervous system diseases or poor compliance.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No